| Valuation method | Value, CHF | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 36.66 | 555 |
| Intrinsic value (DCF) | 8.15 | 46 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
DocMorris AG (SIX: DOCM) is a leading Swiss e-commerce pharmacy and wholesale distributor of medical and pharmaceutical products, operating under brands like Zur Rose, PromoFarma, TeleClinic, and DocMorris. Founded in 1993 and headquartered in Frauenfeld, Switzerland, the company serves both B2C and B2B markets, offering prescription and over-the-counter medicines, health supplements, beauty products, and digital healthcare services. DocMorris combines online and offline retail through its mail-order pharmacies and stationary pharmacy shops, catering to physicians, pharmacies, and private consumers. The company rebranded from Zur Rose Group AG in 2023 to strengthen its digital-first healthcare positioning. With a revenue of CHF 1.02 billion (2024), DocMorris is a key player in Europe’s digital pharmacy sector, though it faces profitability challenges amid regulatory pressures and competitive e-pharmacy expansion.
DocMorris AG presents a high-risk, high-reward investment case due to its strong e-pharmacy market presence but persistent profitability struggles. The company’s revenue base (CHF 1.02B in 2024) reflects solid demand, yet net losses (CHF -97.3M) and negative operating cash flow (CHF -26.6M) raise concerns about near-term sustainability. A high beta (1.87) signals volatility, likely tied to regulatory risks in Europe’s pharmacy sector and competition from deep-pocketed rivals. The lack of dividends and reliance on digital adoption trends may appeal to growth investors, but execution risks—including debt (CHF 312M) and cash burn—warrant caution. Long-term potential hinges on scaling TeleClinic’s digital health services and cost optimization.
DocMorris competes in the fragmented European e-pharmacy market, where its strengths include a multi-brand strategy (Zur Rose, DocMorris), hybrid online-offline distribution, and a foothold in Switzerland and Germany. However, its competitive position is pressured by regulatory hurdles (e.g., Germany’s mail-order pharmacy restrictions) and pricing wars. The company’s wholesale arm provides B2B stability, but B2C margins are squeezed by pure-play rivals like Shop Apotheke. TeleClinic’s telehealth integration offers differentiation, yet scaling this profitably remains unproven. DocMorris lags behind larger players in technological investment (e.g., AI-driven personalization) and lacks the global footprint of US-based giants. Its Swiss base ensures quality trust but limits growth versus EU-centric competitors. The 2023 rebranding signals a sharper focus, but execution must improve to justify its valuation (CHF 440M market cap) amid sector consolidation.